Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)
Complete title: A Phase III Clinical Trial Evaluating TheraSphere(R) in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
The effectiveness and safety of TheraSphere will be evaluated in patients with colorectal cancer with metastases in the liver, who are scheduled to receive second line chemotherapy. All patients receive the standard of care chemotherapy with or without the addition of TheraSphere.
** For Eligibility information, please click on the "Look up trial at NIH" link above. **
Other eligibility criteria may apply.
|Seattle Cancer Care Alliance Intake Office
|800-804-8824 / 206-606-1024
Colon Cancer; Rectal Cancer; Solid Tumors
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.